NASDAQ:PODD - Free Report ) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 53,290 shares of the medical instruments supplier's stock, valued at approximately $11,563,000. Los Angeles Capital Management LLC owned 0.08% of Insulet at the end of the most recent quarter.
Get Insulet alerts:
Sign Up
A number of other hedge funds have also modified their holdings of the stock. Natixis Advisors L.P. boosted its holdings in shares of Insulet by 185.0% in the 4th quarter. Natixis Advisors L.P. now owns 29,883 shares of the medical instruments supplier's stock worth $6,484,000 after acquiring an additional 19,396 shares in the last quarter. LGT Group Foundation bought a new position in shares of Insulet in the fourth quarter valued at about $238,000. First Trust Direct Indexing L.P. acquired a new position in Insulet during the 4th quarter worth about $305,000. Paces Ferry Wealth Advisors LLC bought a new stake in Insulet during the 4th quarter worth about $232,000. Finally, Beck Bode LLC acquired a new stake in Insulet in the 4th quarter valued at about $10,716,000.
Analyst Ratings Changes PODD has been the subject of a number of recent research reports. Stifel Nicolaus boosted their price target on shares of Insulet from $163.00 to $208.00 and gave the stock a "hold" rating in a research note on Monday, February 5th. Barclays lowered their price objective on shares of Insulet from $214.00 to $213.00 and set an "equal weight" rating for the company in a research report on Monday, February 26th. Piper Sandler lowered their price target on Insulet from $250.00 to $230.00 and set an "overweight" rating for the company in a report on Friday, February 23rd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Insulet from $190.00 to $225.00 and gave the stock an "overweight" rating in a report on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $243.21.
Read Our Latest Stock Report on Insulet
Insider Buying and Selling at Insulet In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the firm's stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link . Company insiders own 0.47% of the company's stock.
Insulet Stock Performance NASDAQ PODD traded up $1.01 during trading on Friday, reaching $174.43. The company's stock had a trading volume of 614,615 shares, compared to its average volume of 712,105. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $335.91. The firm has a 50 day moving average price of $169.57 and a 200 day moving average price of $180.95. The firm has a market capitalization of $12.21 billion, a price-to-earnings ratio of 59.94, a price-to-earnings-growth ratio of 3.14 and a beta of 1.00. The company has a current ratio of 3.51, a quick ratio of 2.62 and a debt-to-equity ratio of 1.86.
Insulet (NASDAQ:PODD - Get Free Report ) last announced its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The firm had revenue of $509.80 million for the quarter, compared to the consensus estimate of $461.26 million. During the same period in the prior year, the company posted $0.55 earnings per share. The business's revenue for the quarter was up 37.9% on a year-over-year basis. As a group, equities analysts anticipate that Insulet Co. will post 3.08 EPS for the current fiscal year.
About Insulet (
Free Report )
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Read More
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
